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Abstract
Background: Changes in the density and expression of histamine receptors (HRH) have been
detected in Parkinson's disease (PD) patients, and HRH antagonists bring about improvements in
motor and other symptoms, thus suggesting that HRH play a role in the clinical response of PD
patients. This study is aimed to analyse polymorphic variations of HRH in patients with PD.
Methods: Leukocytary DNA from 195 PD patients and a control group of 231 unrelated healthy
individuals was studied for the nonsynonymous HRH1Leu449Ser and the promoter HRH2G-
1018A polymorphisms by using amplification-restriction analyses.
Results: The HRH1Leu449Ser amino acid substitution was identified in two women with late-
onset PD whereas it was not observed among healthy subjects. The HRH2G-1018A polymorphism
was observed with allele frequencies = 3.59 (95% CI = 1.74–5.44) and 5.0 (95% CI = 3.00–6.96) for
patients with PD and healthy controls, respectively. These frequencies were independent of gender
and age of onset of the disease. Multiple comparison analyses revealed that differences were not
statistically significant.
Conclusion: These results indicate that the polymorphisms analyzed are not a major risk factor
for PD, although the HRH1Leu449Ser amino acid substitution might be related to PD.
Background
Histamine is involved in neuronal degeneration [1] and
neurotoxicity [2]. Changes in the morphology and
increase in density of histaminergic fibers in the substan-
tia nigra have been described in the brain of PD patients
[3]. It has been shown that histamine causes selective
damage in the dopaminergic neurons of the substantia
nigra with induction of inflammatory signal processes [4].
Among patients with PD, blood histamine levels [5] and
the concentration of the histamine metabolite pros-meth-
ylimidazoleatic acid in the cerebrospinal fluid are
increased [6], and recently we described the association of
genotypes leading to high histamine metabolism with
increased risk to develop PD [7]. Taken together, these
findings suggest that modulation of brain histamine may
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be related to PD, but the mechanisms underlying such
modulation remains unknown.
Changes in the density and expression of histamine recep-
tors (HRH) have been detected in PD patients [8]. HRH
antagonists bring about improvements in motor and
other symptoms [9,10], thus suggesting that HRH play a
role in the clinical response of PD patients. Since genes
coding for HRH are polymorphic it may be speculated
that variations in genes coding for HRH could be related
to PD.
Three receptors, HRH1 through HRH3 are present in the
human brain. HRH1 and HRH2 have been localized to
caudate and putamen, and HRH3 is most abundant in the
basal ganglia, the highest density being observed in the
globus pallidus [11]. The predominant location of HRH2
and HRH3 in the basal ganglia suggests that these recep-
tors could play a role in motor functions [11]. In addition,
it has recently been shown that a protective role against
toxic-induced neurodegeneration is linked to expression
of histamine receptors [12]. Taking together the alteration
in histaminergic transmission observed in patients with
PD, the fact that brain histamine receptors are believed to
regulate the release of brain histamine and other neuro-
transmitters [13-16] and the putative role of histamine
receptors in motor functions, it can be speculated that
individuals carrying mutated histamine receptors may
show altered susceptibility to develop PD.
Studies involving single nucleotide polymorphisms
(SNP) in HRH in PD patients are scarce and controversial.
HRH1 and HRH2 are polymorphic due to genetic altera-
tions, whereas no variant HRH3 alleles have been
described so far, with the exception of a rare Ala280Val
described in a patient suffering from Shy-Drager syn-
drome which was not identified in other subjects [17].
The HRH1  gene, located in chromosome 3p25, shows
diverse SNPs, and one of these, designated as rs2067470,
located in exon 3 T1522C, causes the amino acid substitu-
tion Leu449Ser [18]. Other HRH1 variant alleles causing
amino acid changes at positions 19, 270, 308 and 349
have been described [19], but none of these have been
identified in Caucasian individuals [20]. Among the SNPs
mapped to the HRH2  gene, located in chromosome
5q35.2, in addition to the variant HRH2 allele causing the
Asn217Asp amino acid change, initially described by
Orange et al [21,22] but not confirmed by independent
studies [19,23], other variant HRH2  alleles have been
described, although none of these cause amino acid
changes [19,24]. Only one SNP, designated as rs2067474,
a G-1018A transition located in an enhancer element of
the gene promoter, occurs with a relevant allele frequency
[18].
It can be hypothesized that genetic variations in histamine
receptors may modulate the risk to develop PD because
polymorphisms at histamine receptors are likely to have
relevant functional effects, although the functional char-
acterization for histamine receptor polymorphisms has
not been completed so far. For instance, it has been
shown that the HRH1 Leu449Ser is related to the risk to
develop schizophrenia. Although the mechanism
involved in such association remains to be elucidated
[18], the presence of serine, which is more hydrophillic
and reactive than leucine, is likely to induce functional
changes in the receptor. The other SNPs tested at the
HRH1 gene, namely Gly270Glu, induces a change from a
small to a medium-size and acidic amino acid. The HRH2
SNP occurs in an enhancer element of the gene promoter
[23]. It is likely that the HRH2 variant located in the pro-
moter may induce changes in the expression of receptors.
This study is aimed to test the hypothesis that genetic
alterations in histamine receptors, either causing changes
in the expression or functional alterations related to
amino acid substitutions, may cause an increased risk to
develop PD. The HRH gene products may have functional
relevance to PD as they encode histamine receptors, and
hence may influence histamine effects on CNS. In an
attempt to identify factors related to PD risk, we mapped
common SNPs in the HRH1 and HRH2 genes in patients
with PD and healthy subjects.
Methods
All the participants were Caucasian Spanish individuals
and were included in the study after giving informed con-
sent. We studied a cohort of 195 patients suffering from
sporadic PD who presented to the neurological service in
la Princesa Hospital, Madrid, Spain. All consecutive
patients diagnosed by consultant neurologists according
to the criteria recommended by Hughes et al. [25] were
requested to participate, and all of them agreed. Healthy
subjects (n = 231) were randomly selected among medical
students, and university and hospital staff. A medical
examination was performed to identify subjects in good
health. Over 95% of the healthy subjects propositioned
agreed to participate. All lived in the same areas as the
patients (Madrid and surrounding areas). The protocol of
the study was approved by the Ethics Committees of the
hospitals involved in the study. Table 1 summarizes the
demographic data of the subgroups analyzed in the study.
To test for a putative age-related difference in the fre-
quency for the SNPs analyzed, we examined the frequen-
cies of HRH variant alleles in a group of 41 healthy
Spanish nonagenarians free of neurodegenerative diseases
who had participated in previous genetics studies [26].
Genomic DNA was obtained from peripheral leukocytes
and purified according to standard procedures. The pres-
ence of the SPNs was investigated by amplification-restric-BMC Medical Genetics 2008, 9:15 http://www.biomedcentral.com/1471-2350/9/15
Page 3 of 6
(page number not for citation purposes)
tion and electrophoresis in agarose gels. In order to
prevent false-positive or negative findings due to lack of
endonuclease digestions, the detection methods were
designed including both constitutive and polymorphic
restriction sites for the two SNPs analyzed. The analysis of
the HRH1 Gly270Glu rs7651620 polymorphism was car-
ried out after the amplification of a gene fragment of exon
3 by using the following primers (based on the published
human HRH1 sequence Gene Bank Accession No.
NM_000861): TTC ATG CAG CAG ACC TCG GTG and
AGG CCC TGC TCA TCT GTC TTG. After an initial step of
3 minutes at 94°C, PCR amplification was carried out for
40 cycles of 25 sec at 94°C, 1 minute at 56°C, and 1
minute at 72°C, and a final extension period of 5 minutes
at 72°C. The 512 bp PCR product contains a constitutive
restriction site for the endonuclease HinfI, and a variant-
allele specific restriction site. After endonuclease digestion
the wild-type gene yielded fragments of 259 and 253 bp,
whereas the mutated gene was digested to fragments of
259, 205 and 48 bp. No variant alleles for the rs7651620
polymorphism were detected among PD patients or con-
trol subjects.
The analysis of the HRH1 Leu449Ser rs2067470 polymor-
phism was carried out after the amplification of a gene
fragment by using the primers (based on the published
human HRH1 sequence Gene Bank Accession No.
NM_000861): CGAACGGACTCAGATACCACC and
CTGGCAACACACAGGCCTTC. After an initial step of 3
minutes at 94°C, PCR amplification was carried out for 40
cycles of 25 sec at 94°C, 1 minute at 55°C, and 1 minute
at 72°C, and a final extension period of 5 minutes at
72°C. The 470 bp PCR product was sequenced as follows:
The sequencing mixture contained 2 μl of the purified
PCR products and 60 nM of the corresponding primer,
and was assembled according the instructions of the man-
ufacturer (dRhodamine terminator cycle sequencing kit,
Applied Biosystems). Automated sequencing was carried
out in an Abi Prism 310 genetic analyzer (Applied Biosys-
tems). The sequencing conditions were as described else-
where [27].
Regarding the G-1018A transition in the HRH2 gene, the
following primers (based on the HRH2 gene sequence
Gene Bank Accession No. AB023486) were used: ACA
GCC CGT GGC TAA GAA TGG and AGA AGG GAG GCA
GGA TGC AAG. After an initial step of 3 minutes at 94°C,
PCR amplification was carried out for 40 cycles of 25 sec
at 94°C, 1 minute at 62°C, and 1 minute at 72°C, and a
final extension period of 5 minutes at 72°C. The ampli-
fied 574 bp contained three constitutive restriction sites
for the endonuclease BsuRI, yielding fragments of 262,
148, 125 and 39 bp. One of the restriction sites was lost in
the variant allele which after digestion yielded fragments
of 410, 125 and 39 bp. Control DNA samples with known
sequences that were wild-type, heterozygous and
homozygous for every SPN analyzed were ran in parallel
to ensure accurate genotyping.
The statistical power with the sample size finally involved
in the study (n = 195) was 98.5% for the HRH1 variant
allele and 98.1% for the for the HRH2 variant allele (uni-
lateral association). The frequencies for the HRH  were
estimated by counting genes and calculating sample pro-
portions. Case-control analyses were performed with the
χ 2 statistics or Fisher exact test, each when appropriate.
The association between HRH polymorphisms and gen-
der or age of onset of PD was estimated by odds ratio
(OR) with 95% confidence interval (CI). To assess
whether allelic variants influence synergically upon the
age of onset of PD, subjects were classified as carriers and
noncarriers of nonsynonymous SNPs. The above-cited
test was used for the comparison of carriers and noncarri-
ers. Logistic regression analysis was performed to assess
whether HRH gene polymorphisms were correlated with
gender-related risk or age of onset. Association was
expressed as OR with 95% CI. Statistical analysis was per-
formed using the Statistical Package for the Social Sciences
(SPSS) version 10.07 for Windows (SPSS Inc., Chicago, Ill.
USA). Statistical analyses were adjusted for multiple com-
parisons by the use of Bonferroni's test. A two-tailed p
value equal to or less than 0.01 was considered significant.
Results
The fragments of both histamine receptor genes contain-
ing the polymorphisms to be analyzed were amplified in
all participants, and in all cases the products of gene
amplifications had identical sizes. Table 2 shows the gen-
otypes of PD patients and controls. Individuals carrying
the HRH1 SNP were identified among PD patients, but
not in the control group. Regarding HRH2 genotypes, a
lower frequency for variant alleles was observed among
Table 1: Characteristics of the individuals included in the study.
PATIENTS WITH PD (%) HEALTHY SUBJECTS (%)
Men 93 (47.7) 110 (47.6)
Women 102 (52.3) 121 (52.3)
Age ± sd (range) 69.3 ± 22.0 (28–90) 28.9 ± 12.5 (19–84)BMC Medical Genetics 2008, 9:15 http://www.biomedcentral.com/1471-2350/9/15
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PD patients, although the differences were not statistically
significant. Both patients and controls were in Hardy-
Weinberg equilibrium for the HRH1  and  HRH2  geno-
types, with expected frequencies for subjects with the
wild-type, heterozygous and homozygous genotype as
follows:  HRH1  genotype = 99.0%, 1.0% and 0% for
patients and 100.0%, 0% and 0% for healthy subjects;
HRH2 genotype = 92.9%, 6.9% and 0% for patients and
90.3%, 9.5% and 0.2% for control subjects. These
expected frequencies are close to the actual frequencies
shown in Table 2. To test for putative age-related differ-
ences for allele frequencies in the control population, we
analyzed both polymorphisms in nonagenarians. The
allele frequencies among nonagenarian subjects were
identical to those present in the group of 231 healthy indi-
viduals: 0% and 4.9% of variant alleles for the HRH1 and
HRH2 polymorphisms, respectively. No gender or age-
related differences in genotypes or allele frequencies were
observed in the control group.
Patients were subdivided into groups according to gender
and age of onset of symptoms. Table 3 shows that variant
HRH1 alleles are observed among women with late-onset
PD. However, because of the low frequency for these
SNPs, the results were not statistically significant for mul-
tiple comparison values. No major differences regarding
gender or age of onset were observed among PD patients
with regard to the HRH2 polymorphism.
Discussion
The etiology of idiopathic PD is complex and poorly
understood, although epidemiological data and animal
models involve both genetic and environmental factors in
the etiology of the disease [28-31]. Initially promising
findings of genomewide association analyses [32] were
not confirmed by further studies [33-37]. Nevertheless,
evidence of an inheritance role is still supported by the
fact that 6% to 33% of PD patients have relatives with the
disease [38-41]. In the present study we investigated the
role of polymorphisms of histamine-receptors in PD. The
Table 2: Histamine receptor polymorphisms in patients with PD and healthy controls.
GENOTYPE PATIENTS WITH PD NO (%) HEALTHY SUBJECTS NO (%) INTERGROUP COMPARISON VALUES ODDS RATIO 
(95% C.I) [CHI-SQUARE; P VALUE]
H1 Leu/Leu 193 (99.0) 231 (100) 0.46a (0.46–1.34) [2.38; 0.123]
H1 Leu/Ser 2 (1.0) 0 --- 2.20 a (0.75–2.20) [2.38; 0.123]
H1 Ser/Ser 0 --- 0 --- ---
H2 -1018 G/G 183 (93.9) 208 (90.0) 1.69 (0.83–3.44) [2.03; 0.154]
H2 -1018 G/A 10 (5.1) 23 (10.0) 0.49 (0.23–1.04) [3.44; 0.063]
H2 -1018 A/A 2 (1.0) 0 --- 2.20 a (0.75–2.20) [2.38; 0.123]
Total 195 231
HRH1 Allele frequency
H1 Leu 388 (99.5) 462 (100) 0.46 a (0.46–1.34) [2.37; 0.124]
H1 Ser 2 (0.5) 0 (0) 2.19 a (0.74–2.19) [2.37; 0.124]
Total 390 462
HRH2 Allele frequency
H2 -1018 G 376 (96.4) 439 (95.0) 1.41 (0.72–2.74) [0.98; 0.322]
H2 -1018 A 14 (0.6) 23 (5.0) 0.71 (0.37–1.39) [0.98; 0.322]
Total 390 462
Crude Odds ratios are shown. (a) In cases where comparison values included zero the relative risk ratio is shown instead of the Odds Ratio.
Table 3: Histamine receptor polymorphisms according to gender and age of onset of PD. PD patients were subdivided in groups 
according to age of onset (under or over the median age) and according to gender.
PD PATIENTS H1 SER N (OR; 95 C.I.) 
[Χ2; P VALUE]
PD PATIENTS H2 – 1018 A N (OR; 95 
C.I.) [Χ2; P VALUE]
CONTROL SUBJECTS H2 – 1018 A N
Overall patients 2 (2.19 a; 0.74–2.19) [2.37,0.123] 14 (0.71; 0.37–1.39) [0.98, 0.322] 23
Men 0, (--) 3 (0.28; 0.08–0.95) [4.17,0.041] 12
Women 2 (2.19 a; 0.74–2.20) [2.37,0.123] 11 (1.20; 0.52–2.76) [0.16, 0.681] 11
Onset under 68 yr 0, (--) 6 (0.58; 0.24–1.42) [1.36, 0.244] N.A.
Onset over 68 yr 2 (3.45 a; 1.19–3.48) (4.92;0.027) 8 (0.85; 0.38–1.90) [0.154, 0.695] N.A.
(a) In cases where comparison values included zero the relative risk ratio is shown instead of the Odds Ratio.
N.A. Not applicable.
Chi-square and p values correspond to a Mantel-Haenszel comparison with healthy individuals.BMC Medical Genetics 2008, 9:15 http://www.biomedcentral.com/1471-2350/9/15
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rationale for the study is that histamine seems to play a
role in PD and that among the three histamine receptors
present in the brain, two of them, namely HRH1 and
HRH2 are polymorphic.
It should be emphasized that in the present study patients
and controls were not age-matched. Nevertheless, we
observed that age-related differences in allele frequencies
do not occur in healthy subjects. It cannot be ruled out
that some control individuals would eventually develop
PD. Nevertheless, the possibility that some healthy sub-
ject would eventually develop PD in the lapse between the
mean age of controls and the mean age of cases is negligi-
ble given the prevalence of PD (<1%) at ages less than 68
years in the studied population [42], and therefore the dif-
ferences in the mean age of patients and controls should
not influence the findings obtained in the present study.
The HRH1 variant allele frequency in our study popula-
tion is extremely low. We have demonstrated the occur-
rence of the Leu449Ser HRH1 amino acid polymorphism
in two Caucasian women with PD, but this variant allele
was not detected in 231 healthy subjects. Such low fre-
quency is in contrast with the allele frequency initially
reported for the variant allele [43], but it agrees with the
absence of such variant allele in 58 European individuals
that participated in the Hap-Map project [44]. The HRH2
variant allele frequency in our population study, as calcu-
lated from Table 2, is 3.5% in PD patients and 4.9% in
healthy subjects. Such frequency is lower as that initially
reported [23]. Although the occurrence of ethnic differ-
ences between different Caucasian subjects such as Swed-
ish, French or Spanish individuals regarding HRH variant
alleles has not been investigated in detail such differences
may occur, as it has been demonstrated for common SNPs
on genes coding for drug-metabolizing enzymes [45].
Another possible explanation for differences in HRH2
allele frequencies between the present study and that by
Ito et al. [23] is related to sampling. In our study we ana-
lyzed 231 unrelated healthy subjects, whereas in the study
by Ito et al. [23] authors analyze only 53 Swedish subjects
and 52 French subjects. In addition, the Swedish subjects
such study belonged to 15 families and therefore these
were not unrelated subjects. The combination of the low
sample size and the fact that some participants are rela-
tives may cause a bias in allele frequencies. In addition, it
should be mentioned that our findings agree with the
presence of such variant allele with a frequency of 4.2% in
60 European individuals that participated in the Hap-Map
project [46], which is very close to the frequency of 4.9%
reported here (Table 3). In summary, the findings
obtained in the present study do not support the high
allele frequencies initially reported for the variant alleles
analyzed [23,43]. The design of the amplification-restric-
tion method including constitutive and polymorphic
restriction sites and the use of sequencing in the present
study ensures accurate genotyping. This adds to the
increasing evidences indicating that several variant HRH
alleles are actually rarer than initially expected [19,23].
Conclusion
With regard to PD risk, due the low frequency of the pol-
ymorphisms we cannot reach a conclusion of whether
HRH polymorphisms can be considered as low-pene-
trance genes for PD risk with the sample size analyzed.
Further studies and/or meta-analyses would elucidate this
point. However, besides the low allele frequency observed
in patients and control subjects, our findings indicate
both HRH variant alleles show similar frequencies in both
groups, making it unlikely that the studied polymor-
phisms are major risk factors for the development of PD.
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